To judge whether an Amplatzer Septal Occluder (ASO) can be used as a safe therapy
instead of surgery for closure of large atrial septal defects> 25 mm in diameter, we report our …

Little is known about the efficacy and safety of the 40 mm Amplatzer septal occluder (ASO).
Thirty‐three patients (22 female, 11 male) with a large secundum atrial septal defect (ASD) …

BACKGROUND: The Amplatzer Septal Occluder (ASO)(AGA Medical Corp, Golden Valley,
Minn) has gained wide acceptance for transcatheter closure of atrial septal defect (ASD). We …

Background—Prospective data on the medium-term safety and effectiveness of the
AMPLATZER Septal Occluder in clinical practice are not available. The objective of this …

The impact of device size choice on closure results was analyzed in 138 (101 females, 37
males; age 0.5–84.0 years) consecutive patients who underwent transcatheter closure of the …

Background: Transcatheter closure of atrial septal defects (ASDs) has become an alternative
to open surgical procedures. The Amplatzer septal occluder (ASO) has been approved since …

Amplatzer septal occluder (AGA Med. Co., USA) is a novel device for occlusion of atrial
septal defect. We present our experience of transcatheter closure of atrial septal defects …

Percutaneous transvenous closure of atrial septal defects (ASDs) has become feasible in
recent years, as later‐generation devices have largely overcome initial difficulties in device …

Transcatheter closure of atrial septal defects (ASDs) was performed mainly in children and
adolescents. Information about outcome and complications in adults was limited. From …

Device closure of oval fossa atrial scptal defects with the Amplatzer Septal Occluder was
performed in 26 patients ranging in age from 0.89 to 60.44 years. In eight additional patients …